

President Freight Forwarding (Qualifying Individual), Kim Kyung Bae, CEO, Application Type: QI Change

Golden Freight, Inc. dba Saigon Express (OFF & NVO), 510 Parrott Street, #2, San Jose, CA 95112. Officer: Chi T. Hoang, CEO/CFO/Secretary (Qualifying Individual), Application Type: Add NVO Service

Grupo Tical Holding, Inc. dba GTH Corporation (OFF & NVO), 7701 NW. 46th Street, Doral, FL 33166. Officers: Albert Oses, Secretary/Treasurer (Qualifying Individual), Luis A. Ramirez, President, Application Type: New OFF & NVO License

Interport Logistics, LLC (OFF & NVO), 2000 NW. 84th Avenue, Doral, FL 33122. Officer: Alberto J. Marino, Manager (Qualifying Individual), Application Type: Business Structure Change

International Logistic Services, Inc. (OFF & NVO), 155–11 146th Avenue, Jamaica, NY 11434. Officers: Cora R. Fong, Vice President (Qualifying Individual), Jean P. Noens, President/Secretary/Treasurer, Application Type: QI Change

JWJ Express Inc. (OFF & NVO), 149–23 182nd Street, Suite 100, Jamaica, NY 11413. Officers: Charles Wu, Vice President/Secretary (Qualifying Individual), Saughwan Lee, President/Treasurer, Application Type: QI Change

Login Logistics USA, Corp. (NVO), 1345 NW. 98th Court, Bldg. A, Unit 9, Doral, FL 33172. Officers: William Medina, Director/Secretary (Qualifying Individual), Rodinilson B. da Silva, Director/President, Application Type: New NVO License

M.O.T. Intermodal Shipping USA, Inc. (OFF & NVO), 1200–C Scottsville Road, Rochester, NY 14624. Officers: Danielle M. Hogancamp, Vice President/Secretary (Qualifying Individual), Ole Enderslev, President/Treasurer, Application Type: Add NVO Service

Net Cargo LLC (OFF & NVO), 9619 NW. 33rd Street, Doral, FL 33178. Officers: Victor E. Segura/General Manager Member/Treasurer (Qualifying Individual), Jorge A. Paez, Manager Member/Secretary, Application Type: New OFF & NVO License

Overseas Cargo Inc. (OFF & NVO), 332 S. Wayside Drive, Houston, TX 77011. Officer: Mohammed S. Mohamed, CEO (Qualifying Individual), Application Type: New OFF & NVO License

Pacific Republic West Inc. (OFF & NVO), 420 McKinley Street, Suite 111–209, Corona, CA 92879. Officer: Haiying L. Snider, Secretary

(Qualifying Individual), Application Type: New OFF & NVO License

Pactrans Global, LLC (OFF & NVO), 950 Thorndale Avenue, Elk Grove Village, IL 60007. Officers: Chance Pon, Managing Member (Qualifying Individual), Kitty Pon, Manager, Application Type: New OFF & NVO License

Skylink Global Logistics, Inc. (OFF & NVO), One Industrial Plaza, Bldg. C, Valley Stream, NY 11581. Officers: Toru Mizuno, Vice President/Secretary (Qualifying Individual), Kevin Connolly, President/Treasurer, Application Type: New OFF & NVO License

Shipping Solutions Worldwide, Ltd. (OFF & NVO), 14650 Rothgeb Drive, Unit P, Rockville, MD 20850. Officers: Raul Zambrano, Vice President (Qualifying Individual), Edgar Zambrano, President, Application Type: New OFF & NVO

Talwin Transport Service LLC (OFF & NVO), 8305 NW. 27th Street, Suite 111, Doral, FL 33122. Officers: Orestes G. Wrvs, Secretary/Treasurer/MGRM (Qualifying Individual), Gabriel N. Taberna, President/MGRM, Application Type: New OFF & NVO

Transoceanic Projects Development Company, Inc. dba AKL Shipping, Company (OFF & NVO), 1801 Kingwood Drive, Suite 270, Kingwood, TX 77339. Officers: Richard W. Castaing, Executive Vice President (Qualifying Individual), Arval D. Headrick, Sr., President, Application Type: New OFF & NVO License

Transworld Logistics & Shipping Services, Inc. dba All Cargo, Movers Inc. dba Balaji Shipping (U.K.) Limited dba TLSS, Inc. (OFF & NVO), 200 Middlesex Essex Turnpike, Suite 200, Iselin, NJ 08830. Officers: Allan J. Couto, Vice President (Qualifying Individual), Sivaswamy I. Ramakrishnan, President, Application Type: Add NVO Service/Trade Name Change

Viva Logistics Inc. (OFF & NVO), 347 Fifth Avenue, #910, New York, NY 10016. Officers: Shao F. Lai, Vice President (Qualifying Individual), Wheiyu Wang, President, Application Type: New OFF & NVO License

Dated: July 2, 2010.

Karen V. Gregory,
Secretary.

[FR Doc. 2010–16734 Filed 7–8–10; 8:45 am]

BILLING CODE P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) and the Assistant Secretary for Health have taken final action in the following case:

Gerardo L. Paez, PhD, University of Pennsylvania: Based on the reports of an inquiry and an investigation conducted by the University of Pennsylvania (UP) and analysis conducted by the ORI Division of Investigative Oversight (DIO), ORI found that Gerardo L. Paez, PhD, former postdoctoral fellow, Section of Medical Genetics, UP School of Veterinary Medicine, engaged in research misconduct in research supported by National Eye Institute (NEI), National Institutes of Health (NIH), awards R01 EY06855 and R01 EY13132.

ORI found that the Respondent engaged in research misconduct by falsifying and fabricating retinal gene profile data that he purportedly obtained from three-week old normal dogs and dogs with X-linked progressive retinal atrophy.

Specifically, ORI found that:

1. Respondent committed research misconduct by falsifying/fabricating data for gene expression profiles in retinal tissue from three-week old normal dogs and dogs with X-linked progressive retinal atrophy in abstracts and poster presentations for the 2006¹ and 2007² Association for Research in Vision and Ophthalmology (ARVO) meetings and in an unsubmitted manuscript draft.³

2. Respondent falsely labeled data files in the UP bioinformatics core computer and submitted falsely identified files to his research mentors.

Dr. Paez has entered into a Voluntary Settlement Agreement in which he has voluntarily agreed, for a period of three (3) years, beginning on June 9, 2010:

(1) To exclude himself from serving in any advisory capacity to PHS, including

¹Paez, G.L., Zangerl, B., Acland, G.M., & Aguirre, G.D. "Abnormal gene expression profile in retinas with RPCR frameshift mutation."

²Paez, G.L., Zangerl, B., Acland, G.M., & Aguirre, G.D. "Photoreceptor degeneration and tumor suppressor gene expression in canine retinas with RGR frameshift mutation."

³Paez, G.L., Zangerl, B., Acland, G.M., & Aguirre, G.D. "Age-related changes in the transcriptional profile of normal and XLPRAII retinas using a custom cDNA microarray."

but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant;

(2) that any institution that submits an application for PHS support for a research project on which the Respondent's participation is proposed or that uses him in any capacity on PHS-supported research, or that submits a report of PHS-funded research in which he is involved, must concurrently submit a plan for supervision of his duties to the funding agency for approval; the supervisory plan must be designed to ensure the scientific integrity of his research contribution. A copy of the supervisory plan also must be submitted to ORI by the institution. Respondent agreed that he will not participate in any PHS-supported research until such a supervisory plan is submitted to ORI.

FOR FURTHER INFORMATION CONTACT:

Director, Division of Investigative Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453-8800.

John Dahlberg,

Director, Division of Investigative Oversight, Office of Research Integrity.

[FR Doc. 2010-16824 Filed 7-8-10; 8:45 am]

BILLING CODE 4150-31-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Committee on Vital and Health Statistics: Meeting

Pursuant to the Federal Advisory Committee Act, the Department of Health and Human Services (HHS) announces the following advisory committee meeting.

Name: National Committee on Vital and Health Statistics (NCVHS) Standards Subcommittee.

Time and Date: July 19, 2010 9 a.m.-5 p.m. July 20, 2010 8:30 a.m.-5 p.m. July 21, 2010 9 a.m.-5 p.m. (committee discussion)

Place: Hamilton Crowne Plaza Hotel, 1001 14th Street, NW., Washington, DC 20005, (202) 682-0111.

Status: Open.

Purpose: The purpose of this upcoming meeting of the Subcommittee on Standards is to receive industry input on a unique health plan identifier to be used in HIPAA standard transactions, and on new operating rules for standards, and their authoring organizations. The Subcommittee will hear testimony from individuals, organizations and associations on these matters. The subcommittee will meet for three consecutive days for which a variety of panels are scheduled; day one will focus on the unique health plan identifier, day two will concentrate on authoring organizations and operating rules for eligibility and health claim status, and day

three of the meeting will be reserved for Subcommittee discussion and deliberation.

The NCVHS has been named in the Patient Protection and Affordable Care Act (ACA) of 2010 to review and make recommendations on several HIPAA standards and electronic transactions. This meeting will support these activities in the development of a set of recommendations for the Secretary, as required by section 1104 of the ACA. Text of the ACA can be found at http://dpc.senate.gov/dpcdoc-sen_health_care_bill.cfm.

Contact Person For More Information: Substantive program information as well as summaries of meetings and a roster of committee members may be obtained from Lorraine Doo, lead staff for the Standards Subcommittee, NCVHS, Centers for Medicare and Medicaid Services, Office of E-Health Standards and Services, 7500 Security Boulevard, Baltimore, Maryland, 21244, telephone (410) 786-6597 or Marjorie S. Greenberg, Executive Secretary, NCVHS, National Center for Health Statistics, Centers for Disease Control and Prevention, 3311 Toledo Road, Room 2402, Hyattsville, Maryland 20782, telephone (301) 458-4245. Information also is available on the NCVHS home page of the HHS Web site: <http://www.ncvhs.hhs.gov/>, where further information including an agenda will be posted when available.

Should you require reasonable accommodation, please contact the CDC Office of Equal Employment Opportunity on (301) 458-4EEO (4336) as soon as possible.

Dated: June 29, 2010.

James Scanlon,

Deputy Assistant Secretary for Planning and Evaluation, Science and Data Policy, Office of the Assistant Secretary for Planning and Evaluation.

[FR Doc. 2010-16729 Filed 7-8-10; 8:45 am]

BILLING CODE 4151-05-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2010-N-0174]

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Applications for Food and Drug Administration Approval to Market a New Drug; Patent Submission and Listing Requirements and Application of 30-Month Stays on Approval of Abbreviated New Drug Applications Certifying That a Patent Claiming a Drug Is Invalid or Will Not Be Infringed

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing

that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

DATES: Fax written comments on the collection of information by August 9, 2010.

ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, FAX: 202-395-7285, or e-mailed to oira_submission@omb.eop.gov. All comments should be identified with the OMB control number 0910-0513. Also include the FDA docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT:

Elizabeth Berbakos, Office of Information Management, Food and Drug Administration, 1350 Piccard Dr., PI50-400B, Rockville, MD 20850, 301-796-3792, Elizabeth.Berbakos@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.

Applications for FDA Approval to Market a New Drug; Patent Submission and Listing Requirements and Application of 30-Month Stays on Approval of Abbreviated New Drug Applications Certifying That a Patent Claiming a Drug Is Invalid or Will Not Be Infringed—OMB Control Number 0910-0513—Extension

Section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 355(b)(1)) requires all new drug application (NDA) applicants to file, as part of the NDA, "the patent number and the expiration date of any patent which claims the drug for which the applicant submitted the application or which claims a method of using such drug and with respect to which a claim of patent infringement could reasonably be asserted if a person not licensed by the owner engaged in the manufacture[,] use, or sale of the drug." Section 505(c)(2) of the act imposes a similar patent submission obligation on holders of approved NDAs when the NDA holder could not have submitted the patent information with its application. Under section 505(b)(1) of the act, we publish patent information after approval of an NDA in the list entitled "Approved Drug Products With Therapeutic Equivalence Evaluations"